Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiotaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined how Roux-en-Y gastric bypass (RYGB) surgery changes the gut microbiota of morbidly obese patients over time. The researchers used shotgun metagenomic sequencing of fecal DNA to characterize microbial composition at both the species and gene level. They also performed functional annotation of the microbial genes to understand how the metabolic potential of the gut community shifted after surgery. The goal was to describe the taxonomic and functional changes that accompany the weight loss and metabolic improvements known to follow RYGB.
Who was studied?
The study recruited 13 morbidly obese patients scheduled to undergo RYGB surgery. Patients were phenotyped and had stool samples collected before surgery (n = 13), then again at 3 months (n = 12) and 12 months (n = 8) after surgery. This design allowed the same individuals to be followed longitudinally as their own before-and-after comparison.
What were the most important findings?
Gut microbial diversity increased within the first 3 months after RYGB and remained elevated a year later, tracking alongside the weight loss and metabolic improvements the patients experienced. RYGB altered the relative abundance of 31 bacterial species within the first 3 months after surgery. These shifts occurred rapidly and persisted through the 12-month follow-up, indicating the surgery induces a durable restructuring of the individual gut microbiota rather than a transient disturbance.
What are the greatest implications of this study?
The findings support the idea that major, lasting changes in gut microbial community structure accompany the metabolic benefits of RYGB, such as improved insulin sensitivity and glucose homeostasis. Because the diversity and compositional changes appear swiftly and persist for at least a year, the gut microbiota may be an active participant in, rather than a passive bystander to, post-surgical metabolic improvement. This raises the possibility that microbiome-targeted strategies could someday complement or mimic some of the benefits currently achieved only through bariatric surgery.